Growth rate-corrected (GR) dose-response metrics across a panel of 71 breast cancer cell lines treated with a library of small molecule and antibody perturbagens. Dataset 1 of 4: Relative cell counts and normalized growth rate inhibition values across technical replicates. - Dataset (ID:20268)
Download: Excel (XLSX), Comma-separated (CSV)
| Cell | Clinical Subtype | Transcriptional Subtype | Small Molecule | Antibody | Perturbagen Target | Perturbagen Class | Perturbagen Concentration | Perturbagen Conc Unit | Biological Replicate ID | Relative Cell Count | Normalized Growth Rate Inhibition Value | Nominal Division Rate |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| ZR75B | HR+ | Luminal | Baicalein | Lipoxygenase | Metabolism | 0.000427 | uM | 7555.073 | 0.9694 | 0.9623 | 1.6372 | |
| ZR75B | HR+ | Luminal | Baicalein | Lipoxygenase | Metabolism | 0.00213 | uM | 7555.073 | 0.9784 | 0.9735 | 1.6372 | |
| ZR75B | HR+ | Luminal | Baicalein | Lipoxygenase | Metabolism | 0.0107 | uM | 7555.073 | 0.9885 | 0.9859 | 1.6372 | |
| ZR75B | HR+ | Luminal | Baicalein | Lipoxygenase | Metabolism | 0.0533 | uM | 7555.073 | 1.0034 | 1.0041 | 1.6372 | |
| ZR75B | HR+ | Luminal | Baicalein | Lipoxygenase | Metabolism | 0.267 | uM | 7555.073 | 0.9905 | 0.9884 | 1.6372 | |
| ZR75B | HR+ | Luminal | Baicalein | Lipoxygenase | Metabolism | 1.33 | uM | 7555.073 | 0.9369 | 0.9220 | 1.6372 | |
| ZR75B | HR+ | Luminal | Baicalein | Lipoxygenase | Metabolism | 6.67 | uM | 7555.073 | 0.9600 | 0.9507 | 1.6372 | |
| ZR75B | HR+ | Luminal | Baicalein | Lipoxygenase | Metabolism | 33.3 | uM | 7555.073 | 0.7292 | 0.6491 | 1.6372 | |
| ZR75B | HR+ | Luminal | Baicalein | Lipoxygenase | Metabolism | 167 | uM | 7555.073 | 0.5158 | 0.3348 | 1.6372 | |
| 184A1 | NM | Basal | Bortezomib | Proteasome | Proteasome | 0.000427 | uM | 5894.074 | 1.0584 | 1.0796 | 1.4541 | |
| 184A1 | NM | Basal | Bortezomib | Proteasome | Proteasome | 0.000427 | uM | 5894.074 | 1.0584 | 1.0796 | 1.4541 | |
| 184A1 | NM | Basal | Bortezomib | Proteasome | Proteasome | 0.00213 | uM | 5894.074 | 1.0465 | 1.0635 | 1.4541 | |
| 184A1 | NM | Basal | Bortezomib | Proteasome | Proteasome | 0.00213 | uM | 5894.074 | 1.0465 | 1.0635 | 1.4541 | |
| 184A1 | NM | Basal | Bortezomib | Proteasome | Proteasome | 0.0107 | uM | 5894.074 | 0.9292 | 0.9016 | 1.4541 | |
| 184A1 | NM | Basal | Bortezomib | Proteasome | Proteasome | 0.0107 | uM | 5894.074 | 0.9292 | 0.9016 | 1.4541 | |
| 184A1 | NM | Basal | Bortezomib | Proteasome | Proteasome | 0.0533 | uM | 5894.074 | 0.4368 | 0.1315 | 1.4541 | |
| 184A1 | NM | Basal | Bortezomib | Proteasome | Proteasome | 0.0533 | uM | 5894.074 | 0.4368 | 0.1315 | 1.4541 | |
| 184A1 | NM | Basal | Bortezomib | Proteasome | Proteasome | 0.267 | uM | 5894.074 | 0.3789 | 0.0261 | 1.4541 | |
| 184A1 | NM | Basal | Bortezomib | Proteasome | Proteasome | 0.267 | uM | 5894.074 | 0.3789 | 0.0261 | 1.4541 | |
| 184A1 | NM | Basal | Bortezomib | Proteasome | Proteasome | 1.33 | uM | 5894.074 | 0.2666 | -0.1943 | 1.4541 | |
| 184A1 | NM | Basal | Bortezomib | Proteasome | Proteasome | 1.33 | uM | 5894.074 | 0.2666 | -0.1943 | 1.4541 | |
| 184A1 | NM | Basal | Bortezomib | Proteasome | Proteasome | 6.67 | uM | 5894.074 | 0.0693 | -0.6812 | 1.4541 | |
| 184A1 | NM | Basal | Bortezomib | Proteasome | Proteasome | 6.67 | uM | 5894.074 | 0.0693 | -0.6812 | 1.4541 | |
| 184A1 | NM | Basal | Bortezomib | Proteasome | Proteasome | 33.3 | uM | 5894.074 | 0.0665 | -0.6899 | 1.4541 | |
| 184A1 | NM | Basal | Bortezomib | Proteasome | Proteasome | 33.3 | uM | 5894.074 | 0.0665 | -0.6899 | 1.4541 |